An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso

listen audio

Study Justification:
– The study aimed to assess the effect of adding a third dose of sulphadoxine-pyrimethamine (SP) to the standard two-dose intermittent preventive treatment for pregnant women in Burkina Faso.
– Malaria is a major health concern in Burkina Faso, especially for pregnant women, and it is important to evaluate the impact of different treatment strategies on maternal and neonatal health outcomes.
Study Highlights:
– The study found that women who received three doses of SP had a significantly lower incidence of malaria infections compared to those who received two doses.
– Malaria infection during the first trimester of pregnancy was associated with a higher risk of low birth weight.
– The timing of first malaria infection did not affect the risk of maternal anaemia or perinatal mortality.
Study Recommendations:
– Pregnant women should be encouraged to use long-lasting insecticidal nets before and throughout their pregnancy to prevent malaria infection.
– Health facilities should provide three doses of SP as part of the intermittent preventive treatment for pregnant women to reduce the risk of malaria infection and low birth weight.
Key Role Players:
– Health staff at antenatal care clinics and health facilities for enrollment and follow-up of pregnant women.
– Home visitors for identifying and referring pregnant women to health facilities.
– Study pharmacist for packaging and distributing the SP drugs.
– Trained home visitors for administering SP and nutritional supplementation.
– Study obstetrician for assessing gestational age.
– Laboratory staff for collecting and analyzing blood samples.
– Health staff at delivery facilities for examining and weighing newborns.
Cost Items for Planning Recommendations:
– Long-lasting insecticidal nets for pregnant women.
– SP drugs for three-dose intermittent preventive treatment.
– Training and salaries for health staff, home visitors, and laboratory staff.
– Equipment and supplies for blood sample collection and analysis.
– Transportation and logistics for home visits and drug distribution.
– Administrative and management costs for study coordination and monitoring.
Please note that the actual cost of implementing these recommendations would depend on various factors and would need to be determined through a detailed budgeting process.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong, but there are some areas for improvement. The study design is prospective and includes a randomized control group, which increases the validity of the findings. The sample size is also relatively large (1,034 women), which adds to the strength of the evidence. However, there are a few limitations that could be addressed to improve the rating. First, the abstract does not provide information on the methods used to collect and analyze the data, which makes it difficult to assess the quality of the study. Second, the abstract does not mention any potential biases or limitations of the study, which could affect the reliability of the results. To improve the rating, the authors could provide more details on the study methods and acknowledge any limitations or potential biases in the abstract.

Background: A prospective study aiming at assessing the effect of adding a third dose sulphadoxine-pyrimethamine (SP) to the standard two-dose intermittent preventive treatment for pregnant women was carried out in Hounde, Burkina Faso, between March 2006 and July 2008. Pregnant women were identified as earlier as possible during pregnancy through a network of home visitors, referred to the health facilities for inclusion and followed up until delivery. Methods. Study participants were enrolled at antenatal care (ANC) visits and randomized to receive either two or three doses of SP at the appropriate time. Women were visited daily and a blood slide was collected when there was fever (body temperature > 37.5°C) or history of fever. Women were encouraged to attend ANC and deliver in the health centre, where the new-born was examined and weighed. The timing and frequency of malaria infection was analysed in relation to the risk of low birth weight, maternal anaemia and perinatal mortality. Results: Data on birth weight and haemoglobin were available for 1,034 women. The incidence of malaria infections was significantly lower in women having received three instead of two doses of SP. Occurrence of first malaria infection during the first or second trimester was associated with a higher risk of low birth weight: incidence rate ratios of 3.56 (p < 0.001) and 1.72 (p = 0.034), respectively. After adjusting for possible confounding factors, the risk remained significantly higher for the infection in the first trimester of pregnancy (adjusted incidence rate ratio = 2.07, p = 0.002). The risk of maternal anaemia and perinatal mortality was not associated with the timing of first malaria infection. Conclusion: Malaria infection during first trimester of pregnancy is associated to a higher risk of low birth weight. Women should be encouraged to use long-lasting insecticidal nets before and throughout their pregnancy. © 2012 Valea et al; licensee BioMed Central Ltd.

Two peripheral health centres (Koho and Karaba) in the Houndé health district, south-west Burkina-Faso, were selected for the study. In this area, malaria is markedly seasonal with high transmission during the rainy season (June to December) [21]. The district hospital and the 28 peripheral health facilities cover a population of approximately 247,500 people. In 2007, the number of pregnant women at risk of malaria was estimated at 12,500, while malaria was the main disease in the health district, accounting for about 38% of all consultations and 52% of hospitalizations. This was part of a larger study investigating both the effect of multiple micronutrients supplementation (MMS) versus fortified food supplementation (FFS) and that of IPTp/SP, two versus three doses on the health of pregnant women and that of their offspring. Participants were randomized in permuted blocks of four to receive either two doses of SP as recommended by the National Malaria Control Programme (NMCP) or three doses. Randomization numbers were generated by a computer program, sealed in opaque envelopes and opened only when an eligible subject was identified. These numbers were then transmitted to the study pharmacist who packaged the drugs in individual plastic zip bags. Each bag was labelled with the participant's name, identification, residence, and randomization group. The field pharmacist prepared for each woman an individual schedule for SP administration according to the gestational age at randomization and transmitted it to the trained home visitors who administered both SP and either MMS or FSS. Results of the nutrition intervention have been reported elsewhere [22]. The effect of IPTp with three doses of SP versus two doses of SP on LBW and pregnancy outcomes have also been reported in a previous publication [23]. Pregnant women were identified through a community-based network of home visitors, as described elsewhere [22]. All women of child-bearing age in the study area were identified and paid monthly visits during which they were screened for pregnancy. Women suspected to be pregnant were referred to the health facilities for a pregnancy test. The study protocol and procedures were then explained to the potential participants in the local language and those agreeing to participate were asked to provide a written inform consent. Women with known hypersensibility to SP or not planning to stay in the study area for the next two years were excluded. Study participants were recruited at ANC clinics, where the health staff recorded demographic data, medical and pregnancy history. In addition, a clinical examination was performed and vital signs, weight, height and arm circumference were measured. All measures were repeated at each ANC visit. Gestational age was assessed as early as possible by the study obstetrician using trans-abdominal ultrasound fetal biometry. Women included in the study were visited at home daily by the home visitors who recorded the body temperature and registered any complaint. In case of fever (body temperature ≥ 37.5°C) or history of fever since the last visit, a blood sample for thick and thin film was collected and sent to the health district laboratory. All women with a confirmed malaria infection were treated with a full course of quinine (24 mg/kg/day for seven days), regardless of their gestational age. Pregnant women were encouraged to attend their scheduled ANC visits and to deliver at the health facilities where the new-borns was examined, weighed and measured twice by two different members of the health staff. Thick and thin blood smears were collected in duplicate and stained with Giemsa 10% (pH 7.2) for 10 minutes. Parasite densities were determined on the thick smears by counting asexual parasites per 200 white blood cells (WBC) and assuming a WBC count of 8,000/μl. A thick blood smear was considered negative after reading 100 high-power fields. Ten percent of the slides were randomly selected and sent to the Laboratory of Parasitology/Centre Muraz for quality control. Haemoglobin (Hb) was measured by using a portable spectrophotometer (HemoCue, Angelholm, Sweden). The study protocol was approved by the ethical committees of the Centre Muraz, Bobo-Dioulasso, Burkina Faso, and the University of Antwerp, Belgium. The trial was registered in the ClinicalTrial.gov registry (identifier: {"type":"clinical-trial","attrs":{"text":"NCT00909974","term_id":"NCT00909974"}}NCT00909974). The study purpose and procedures where explained to the potential participants by the study clinician in the local languages. Women who fulfilled the inclusion criteria and agreed to participate in the study were asked to provide a written inform consent. A new-born was classified as LBW if the birth weight was < 2,500 g. Women with haemoglobin levels < 11 g/dl were classified as anaemic, those with haemoglobin levels < 8 g/dl were classified as having moderate-to-severe anaemia. Neonatal death was defined as one occurring between delivery and 28 days of life. Malaria infection was defined as a slide positive for Plasmodium falciparum, any density. Incidence rates were computed considering the follow-up duration time (in months) of each woman. Women with a malaria infection after previous treatment with quinine were considered as re-infected. Time to re-infection was defined as the period between the first infection parasite clearance and the second infection. As the parasite clearance was not monitored, we calculated an adjusted time to re-infection considering that all parasites were cleared after three days as indicated in a previous publication [24]. Data were double entered in a Microsoft Access® database by two data clerks. Validation and analysis were performed using Stata 10 IC® software. Only singleton pregnancies were included in the analysis. The Chi2 or Fisher exact test were used to compare proportions for categorical variables while a t-test for normally distributed or Mann-Whitney test for non-normally distributed was used for continuous variables at baseline. A multivariate analysis using a Poisson regression model with robust standard error estimates to evaluate the relationship between explanatory variables and outcomes was also performed. Crude and adjusted incidence rate ratios (IRR) with 95% CI were computed. A p-value ≤ 0.05 was considered as statistically significant. The timing of malaria infection was defined according to the first infection detected at the first, second or third trimester of pregnancy. The frequency of malaria infection was categorized according to the number of positive slides detected during the whole pregnancy, i.e. 0, 1, or ≥ 2. Explanatory variables and possible confounders included the number of SP doses received (two or three), the nutritional supplementation (FFS or MMS), gravidity, body mass index at enrolment (underweight: body mass index < 18.5 kg/m2; or normal weigh, BMI ≥ 18.5 kg/m2), and malaria transmission season at delivery (low transmission season between December and May and high transmission season between June and November).

Based on the provided information, here are some potential innovations that could improve access to maternal health:

1. Mobile Health (mHealth) Solutions: Develop mobile applications or SMS-based systems to provide pregnant women with timely information and reminders about antenatal care visits, medication schedules, and preventive measures against malaria.

2. Community-Based Education and Awareness Programs: Implement community-based programs to educate pregnant women and their families about the importance of antenatal care, early detection and treatment of malaria, and the use of insecticide-treated bed nets.

3. Telemedicine Services: Establish telemedicine services to enable pregnant women in remote areas to consult with healthcare professionals and receive guidance on prenatal care, malaria prevention, and treatment.

4. Integrated Maternal Health Clinics: Set up integrated clinics that provide comprehensive maternal health services, including antenatal care, malaria prevention and treatment, nutrition counseling, and access to micronutrient supplementation.

5. Task-Shifting and Training: Train and empower community health workers to provide basic antenatal care services, administer intermittent preventive treatment for malaria, and conduct health education sessions in their communities.

6. Supply Chain Management: Strengthen the supply chain management system to ensure the availability of essential medicines, including antimalarial drugs, at health facilities and community distribution points.

7. Public-Private Partnerships: Foster collaborations between the public and private sectors to improve access to maternal health services, including the provision of affordable antenatal care, malaria prevention tools, and diagnostic tests.

8. Quality Improvement Initiatives: Implement quality improvement initiatives to enhance the delivery of maternal health services, including the use of standardized protocols, regular monitoring and evaluation, and continuous training of healthcare providers.

9. Health Financing Mechanisms: Explore innovative health financing mechanisms, such as community-based health insurance or conditional cash transfer programs, to reduce financial barriers and increase access to maternal health services.

10. Research and Data Collection: Conduct further research to better understand the barriers to accessing maternal health services and the impact of different interventions, and use this evidence to inform policy and programmatic decisions.
AI Innovations Description
Based on the provided information, the following recommendation can be developed into an innovation to improve access to maternal health:

1. Implement a community-based network of home visitors: Establish a network of trained home visitors who can identify and refer pregnant women to health facilities for antenatal care (ANC) visits. These home visitors can regularly visit women of child-bearing age in the community to screen for pregnancy and provide information on the importance of ANC visits.

2. Improve access to intermittent preventive treatment for pregnant women: Ensure that pregnant women have access to the recommended doses of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria. This can be achieved by providing SP at ANC clinics and through the home visitors who can administer the medication to pregnant women.

3. Promote the use of long-lasting insecticidal nets (LLINs): Encourage pregnant women to use LLINs before and throughout their pregnancy to prevent malaria infection. Provide education and resources on the proper use and maintenance of LLINs.

4. Strengthen ANC services: Enhance the capacity of health facilities to provide comprehensive ANC services, including regular check-ups, screening for malaria infection, and monitoring of maternal and fetal health. This can be done by training healthcare providers, improving infrastructure and equipment, and ensuring the availability of essential supplies and medications.

5. Improve coordination and collaboration between health facilities: Establish a system for sharing information and coordinating care between health facilities in the district. This can help ensure that pregnant women receive consistent and high-quality care throughout their pregnancy, delivery, and postpartum period.

By implementing these recommendations, access to maternal health can be improved, leading to better outcomes for pregnant women and their babies in Burkina Faso.
AI Innovations Methodology
To improve access to maternal health, here are some potential recommendations:

1. Strengthening Antenatal Care (ANC) Services: Enhance ANC services by providing comprehensive care, including regular check-ups, screenings, and education on maternal health issues.

2. Mobile Health (mHealth) Interventions: Utilize mobile technology to provide information and support to pregnant women, such as reminders for ANC visits, educational messages, and access to teleconsultations with healthcare providers.

3. Community-Based Interventions: Implement community-based programs that involve trained community health workers who can provide basic maternal health services, referrals, and support to pregnant women in remote areas.

4. Improving Transportation: Address transportation barriers by providing affordable and accessible transportation options for pregnant women to reach healthcare facilities for ANC visits and delivery.

5. Maternal Health Insurance: Establish or expand health insurance schemes specifically for maternal health, ensuring that pregnant women have access to affordable and quality healthcare services.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the indicators: Identify key indicators to measure the impact, such as the number of ANC visits, percentage of women delivering in healthcare facilities, maternal mortality rate, and neonatal mortality rate.

2. Collect baseline data: Gather data on the current status of maternal health access in the target population, including ANC attendance rates, delivery location, and maternal and neonatal mortality rates.

3. Design interventions: Develop a simulation model that incorporates the recommended interventions and their potential impact on the identified indicators. This could involve estimating the expected increase in ANC attendance, percentage of facility-based deliveries, and reduction in maternal and neonatal mortality rates based on available evidence and expert opinions.

4. Input data and run simulations: Input the baseline data into the simulation model and run multiple simulations to estimate the potential impact of the interventions on the selected indicators. This could involve varying the coverage and effectiveness of each intervention to assess different scenarios.

5. Analyze results: Analyze the simulation results to determine the potential impact of the interventions on improving access to maternal health. Compare the outcomes with the baseline data to assess the effectiveness of the recommendations.

6. Refine and validate the model: Refine the simulation model based on feedback and validation from experts and stakeholders. Incorporate additional data and adjust the model parameters as needed to improve accuracy.

7. Communicate findings: Present the simulation results in a clear and concise manner, highlighting the potential benefits of the recommended interventions in improving access to maternal health. Use the findings to advocate for policy changes and resource allocation to implement the identified interventions.

Partagez ceci :
Facebook
Twitter
LinkedIn
WhatsApp
Email